Cellectis (NASDAQ:CLLS) Earns Buy Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a report published on Thursday. The firm issued a buy rating on the biotechnology company’s stock.

Separately, Barclays decreased their price objective on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th.

Cellectis Stock Down 5.0 %

NASDAQ CLLS opened at $1.33 on Thursday. The firm has a market cap of $73.93 million, a PE ratio of -1.02 and a beta of 3.06. Cellectis has a one year low of $1.32 and a one year high of $3.38. The stock’s 50 day simple moving average is $1.61 and its 200 day simple moving average is $1.89. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CLLS. Wells Fargo & Company MN boosted its position in shares of Cellectis by 103.4% in the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 12,500 shares during the last quarter. Millennium Management LLC bought a new position in shares of Cellectis in the 4th quarter worth $962,000. Finally, B Group Inc. bought a new position in shares of Cellectis in the 4th quarter worth $5,547,000. 63.90% of the stock is currently owned by institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.